Incyte
Incyte Corporation (NASDAQ: INCY) is a global biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary therapeutics. The company maintains research and commercial operations across multiple continents, with significant facilities in Wilmington, Delaware, Morges,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Incyte does
In the company’s own words
Incyte Corporation (NASDAQ: INCY) is a global biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary therapeutics. The company maintains research and commercial operations across multiple continents, with significant facilities in Wilmington, Delaware, Morges, Switzerland, Tokyo, Japan, and Montreal, Canada. Incyte's website is www.incyte.com.
The company operates across three primary therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. In Hematology, Incyte commercializes JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease, along with ICLUSIG (ponatinib), MONJUVI/MINJUVI (tafasitamab), and NIKTIMVO (axatilimab). The Oncology franchise includes PEMAZYRE (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms, and ZYNYZ (retifanlimab) for Merkel cell carcinoma and squamous cell carcinoma of the anal canal. The Inflammation and Autoimmunity segment features OPZELURA (ruxolitinib) cream for atopic dermatitis and vitiligo.
Incyte's business model combines internal drug discovery with strategic collaborations and licensing arrangements. The company maintains exclusive development and commercialization rights to JAKAFI in the United States while licensing ruxolitinib internationally to Novartis under the brand name JAKAVI. Similarly, baricitinib is licensed to Eli Lilly for inflammatory and autoimmune indications, and capmatinib is licensed to Novartis for oncology applications. These arrangements generate milestone payments and royalty revenues.
The company's competitive advantages include proprietary expertise in medicinal chemistry, biologics, and targeted drug discovery, supported by comprehensive in-house capabilities spanning target validation, high-throughput screening, structural biology, and computational drug discovery. Incyte emphasizes a focused pipeline strategy, concentrating resources on selected programs in targeted oncology, myeloid diseases, and dermatology. The company collaborates with academic institutions, contract research organizations, and biotechnology partners to enhance its development capabilities while maintaining control over key therapeutic areas and markets where it believes it can successfully compete.
Company details
- Sector
- Health Care
- Industry (SIC)
- Professional Services
- Headquarters
- WILMINGTON, DE
- Fiscal year end
- December
- CIK
- 879169
- SIC
- 8731
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Incyte — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Incyte’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Incyte and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Incyte's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Incyte's last four quarterly filings that the numbers alone won't show?”